Pfizer Inc. (NYSE: PFE) Q2 2021 Earnings call dated Jul. 28, 2021
Corporate Participants:
Christopher Stevo — Senior Vice President, Chief Investor Relations Officer
Albert Bourla — Chairman and Chief Executive Officer
Mikael Dolsten — Chief Scientific Officer and President, Worldwide Research, Development and Medical
Frank DAmelio — Chief Financial Officer
Angela Hwang — Group President, Pfizer Biopharmaceuticals Group
Analysts:
Kerry Holford — Berenberg — Analyst
Matthew Harrison — Morgan Stanley — Analyst
Daniel Bisbee — RBC Capital — Analyst
Chris Schott — J.P. Morgan — Analyst
Ronny Gal — Bernstein — Analyst
Geoff Meacham — Bank of America — Analyst
Andrew Baum — Citi — Analyst
Carter Gould — Barclays — Analyst
Geoffrey Porges — SVB Leerink — Analyst
Louise Chen — Cantor — Analyst
Terence Flynn — Goldman Sachs — Analyst
_________
To read the full earnings call transcript, click here
Most Popular
CVX Earnings: Chevron reports lower revenue and profit for Q1 2024
Energy exploration company Chevron Corporation (NYSE: CVX) announced first-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation was $5.50 billion or
ABBV Earnings: AbbVie reports lower adj. profit for Q1 2024; revenue edges up
Specialty biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) Friday announced first-quarter 2024 financial results, reporting a decline in adjusted earnings and a modest rise in revenues. The company reported worldwide net
CL Earnings: Key quarterly highlights from Colgate-Palmolive’s Q1 2024 financial results
Colgate-Palmolive Company (NYSE: CL) reported first quarter 2024 earnings results today. Net sales increased 6.2% year-over-year to $5.06 billion. Organic sales increased 9.8%. Net income attributable to Colgate-Palmolive Company was
Listen On
